您现在的位置是:Leisure >>正文
【a fate inked in blood spice level】Sanofi to Withdraw Zantac After FDA Warns of Carcinogens
Leisure599人已围观
简介SanofiSNY will have to withdraw its heartburn drug, Zantac, from U.S. markets, following FDA’s reque ...
Sanofi
SNY will have to withdraw its heartburn drug,a fate inked in blood spice level Zantac, from U.S. markets, following FDA’s request.
The FDA has requested drugmakers marketing ranitidine, which is widely available by the brand name of Zantac, to immediately withdraw all prescription and OTC versions from the market. The FDA in its investigations observed that the ranitidine medications, which are approved for treating heartburn associated with acid indigestion, contain a carcinogenic contaminant, N-Nitrosodimethylamine ("NDMA").
Please note that in October 2019 Sanofi initiated a voluntary recall of all Zantac over-the-counter (“OTC”) versions — Zantac 150, Zantac 150 Cool Mint, and Zantac 75 — in the United States. The decision was made by the company as a precautionary measure following a public statement from the FDA in September, alerting about a possible contamination of ranitidine medications.
Due to recall of Zantac, Sanofi reported that sales of its Consumer Healthcare GBU declined 12.8% in the United States in the fourth quarter 2019. Complete withdrawal of the drug will further impact sales unfavorably in 2020. A few other generic drugmakers marketing ranitidine medications had also initiated voluntary recall of the drugs last year, including Perrigo PRGO and Lannett Company LCI.
Shares of Sanofi have lost 14.6% so far this year compared with the industry’s decrease of 11.1%.
Although low-levels of NDMA do not increase risk of cancer, the FDA has determined that NDMA in some ranitidine products increases with time and when medications are stored at higher than room temperatures. These can lead to consumer exposure to unacceptable levels of NDMA, which the agency states may cause cancer.
However, director of the FDA’s Center for Drug Evaluation and Research stated that though the agency had not observed unacceptable levels of NDMA in many of the samples that were tested, it was unsure of storage duration and conditions of the samples. Hence, as a precaution, the FDA decided that ranitidine medications should not be available to consumers and patients unless its quality can be assured.
With this withdrawal request, ranitidine medications will not be available for new or existing prescriptions or OTC use in the United States. The FDA has suggested alternative drugs for use, including famotidine (Pepcid), cimetidine (Tagamet), esomeprazole (AstraZeneca’s AZN Nexium), lansoprazole (Takeda Pharmaceuticals’ Prevacid) or omeprazole (Prilosec). These medications are not found to contain NDMA.
Story continues
Sanofi Price
Sanofi Price
Sanofi price | Sanofi Quote
Zacks Rank
Sanofi currently carries a Zacks Rank #3 (Hold). You can see
the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here
.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
Sanofi (SNY) : Free Stock Analysis Report
AstraZeneca PLC (AZN) : Free Stock Analysis Report
Perrigo Company plc (PRGO) : Free Stock Analysis Report
Lannett Co Inc (LCI) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
View comments
Tags:
相关文章
Moderna to supply 100 to 125 mln COVID-19 vaccine doses globally in first quarter
LeisureDec 3 (Reuters) - Moderna Inc said on Thursday it expects to have between 100 million and 125 millio ...
【Leisure】
阅读更多FOREX-Yen soars as growth concerns dampen appetite
Leisure* Yen strengthens in Asian trade* Dollar starts 2019 on the back foot* Graphic: World FX rates in 20 ...
【Leisure】
阅读更多What's in a name? Islamic banking rebrands in attempt to go mainstream
Leisure* Islamic banks' growth slows after rapid expansion* So they aim to go after foreign, non-Muslim cus ...
【Leisure】
阅读更多
热门文章
- It's not over until there is no virus anywhere in the world - WHO
- Watch Sacha Baron Cohen salute 'comedy genius' Rudy Giuliani in Golden Globes speech
- Can Applied Development Holdings Limited (HKG:519) Improve Its Returns?
- AZZ (AZZ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
- Callon Petroleum Climbs 4% As 3Q Sales Surge 74%; Street Sticks To Hold
- Yamana Gold-Osisko Mining Announce Partnership
最新文章
-
SoftBank CEO Tells Wall Street He’s Eager to Keep Investing
-
AZZ (AZZ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
-
Sony Announces the α77II (Alpha 77 Mark II) Translucent Mirror DSLR Camera
-
Options Traders React to Box Buyout Buzz
-
Sun Summit Minerals Phase 2 Drilling Update and Completion of IP Survey at the Buck Property
-
Should You Be Pleased About The CEO Pay At Ework Group AB (publ)’s (STO:EWRK)
友情链接
- Copart (CPRT) Gains From Auction Locations Despite High Costs
- UK lawmakers call for 'strong sanctions' on social media companies that fail to safeguard users
- Supply Chain And Logistics Degree Programs On The Upswing
- Marriott revenue, FY forecast miss estimates on weak demand
- Here's How 6 Credit Card Applications in 1 Day Affected My Credit Score
- RBI to allow banks to restructure some defaulting small business loans
- Toronto house prices, listings surge in April but sales dip
- Can We See Significant Insider Ownership On The Bayerische Motoren Werke Aktiengesellschaft (FRA:BMW) Share Register?
- Is Concho Resources Inc. (NYSE:CXO) Excessively Paying Its CEO?
- Cigna: 4Q Earnings Snapshot